Compare JQC & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JQC | DRTS |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.9M | 641.6M |
| IPO Year | N/A | N/A |
| Metric | JQC | DRTS |
|---|---|---|
| Price | $4.78 | $8.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | ★ 801.1K | 242.2K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 11.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $699.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.62 | $2.50 |
| 52 Week High | $5.58 | $8.60 |
| Indicator | JQC | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 44.84 | 63.17 |
| Support Level | $4.69 | $6.37 |
| Resistance Level | $4.89 | $8.60 |
| Average True Range (ATR) | 0.05 | 0.41 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 22.58 | 79.31 |
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.